U.S. Markets closed
  • S&P Futures

    3,812.50
    +18.50 (+0.49%)
     
  • Dow Futures

    30,435.00
    +125.00 (+0.41%)
     
  • Nasdaq Futures

    11,697.50
    +73.75 (+0.63%)
     
  • Russell 2000 Futures

    1,777.60
    +9.60 (+0.54%)
     
  • Crude Oil

    88.14
    +0.38 (+0.43%)
     
  • Gold

    1,729.20
    +8.40 (+0.49%)
     
  • Silver

    20.75
    +0.20 (+0.98%)
     
  • EUR/USD

    0.9916
    -0.0070 (-0.7040%)
     
  • 10-Yr Bond

    3.7590
    +0.1420 (+3.93%)
     
  • Vix

    28.55
    -0.52 (-1.79%)
     
  • GBP/USD

    1.1356
    -0.0119 (-1.0356%)
     
  • USD/JPY

    144.6520
    +0.4530 (+0.3141%)
     
  • BTC-USD

    20,308.96
    +85.98 (+0.43%)
     
  • CMC Crypto 200

    461.72
    +3.31 (+0.72%)
     
  • FTSE 100

    7,052.62
    -33.84 (-0.48%)
     
  • Nikkei 225

    27,310.92
    +190.39 (+0.70%)
     

iXensor Confirms PixoTest® COVID-19 Antigen Test Detects Omicron and Other Key Variants of Concern

·2 min read

TAIPEI, Taiwan, December 22, 2021--(BUSINESS WIRE)--iXensor Co., Ltd. (6734.TWO)

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211222005223/en/

iXensor's PixoTest COVID-19 Antigen Test effectively detects Omicron and other key variants of concern (Photo: Business Wire)

iXensor, the pioneer of mobile health, declares that its computer vision-powered PixoTest® COVID-19 Antigen Test effectively detects all major SARS-CoV-2 variants including Omicron (B.1.1.529) after completing two validation studies.

In response to emerging new waves of the COVID-19 pandemic caused by Omicron across the globe, iXensor has conducted in-silico analysis followed by a laboratory validation using the recombinant protein of the Omicron variant. The in-silico study evaluated the amino acid sequences of N protein wild type and the Omicron variant (P13L, E31del, R32del, S33del, R203K, G204R), concluding that Omicron is detectable by PixoTest® COVID-19 Antigen Test. Furthermore, in the recombinant protein study, PixoTest® achieves the same limit of detection (0.25ng/ml) on those variants of concern as on the original wild type of SARS-CoV-2 used as a control.

Both study results affirm that the PixoTest® COVID-19 Antigen Test can detect the latest Omicron variant effectively in addition to the previous confirmation on SARS-CoV-2 Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2). Most importantly, the sensitivity of PixoTest® COVID-19 Antigen Test is not affected by the Omicron and other Variants of Concern.

Although vaccines have become widely available, Omicron has a higher chance of causing breakthrough infections and fundamentally changing the landscape of the pandemic across the globe. Rapid tests that cannot detect the Omicron variant make for a worrying prospect because false-negative results could potentially lull people into a false sense of security.

The CEO of iXensor, Dr. Carson Chen, commented "Now more than ever, Omicron-detectable frequent testing remains a critical part of COVID-19 response to keep communities open, employees and students safe, and enable people to resume traveling with less fear."

About iXensor
iXensor, the pioneer of mobile health, turns smartphones into lab-grade mobile medical diagnostics. In 2017, iXensor introduced the PixoTest® Blood Glucose Monitoring System as the world's first US FDA-approved smartphone camera-based blood test. Based on the PixoTech® platform, iXensor has ventured into at-home self-testing and clinical point-of-care diagnostics across infectious diseases, women's health, diabetes, diabetes and cardiovascular diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005223/en/

Contacts

Media Contact
Spokesperson: Patrick Liao
Website: www.ixensor.com
Email: pr@ixensor.com
Phone: +886-928-570-208